CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

被引：18
|
作者：
Agha, Mounzer E.
Cohen, Adam D.
Madduri, Deepu
Cohen, Yael C.
Delforge, Michel
Hillengass, Jens
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christof
Schecter, Jordan Mark
De Braganca, Kevin C.
Varsos, Helen
Wang, Liwei
Vogel, Martin
Carrasco-Alfonso, Marlene
Akram, Muhammad
Wu, Xiaoling
Nesheiwat, Tonia
Einsele, Hermann
机构：
[1] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Mt Sinai Med Ctr, New York, NY 10029 USA
[4] Tel Aviv Univ, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel
[5] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[6] Univ Ziekenhuizen Leuven, Leuven, Belgium
[7] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[8] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany
[9] Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[10] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[11] Univ Hosp Heidelberg, Heidelberg, Germany
[12] Univ Cologne, Cologne, Germany
[13] Janssen R&D, Raritan, NJ USA
[14] Janssen Global Serv LLC, Raritan, NJ USA
[15] Legend Biotech USA Inc, Piscataway, NJ USA
[16] Legend Biotech USA Inc, Somerset, NJ USA
[17] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8013
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma After 1-3 Prior Lines of Therapy: Updated Results From CARTITUDE-2 Cohort A
    Cohen, Yael C.
    Cohen, Adam D.
    Delforge, Michel
    Hillengass, Jens
    Goldschmidt, Hartmut
    Weisel, Katja
    Raab, Marc-Steffen
    Scheid, Christoph
    Schecter, Jordan M.
    De Braganca, Kevin C.
    Varsos, Helen
    Yeh, Tzu-Min
    Wang, Liwei
    Vogel, Martin
    Corsale, Christina
    Akram, Muhammad
    Pacaud, Lida
    Nesheiwat, Tonia
    Agha, Mounzer
    Einsele, Hermann
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 34 - 35
  • [22] Use of cilta-cel CAR T cells following previous use of a BCMA-directed CAR T-cell product in heavily treated patients with relapsed/refractory multiple myeloma: a single institution case series
    Attar, Narsis
    Cirstea, Diana
    Branagan, Andrew
    Yee, Andrew
    Frigault, Matthew
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S161 - S161
  • [23] On ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), in patients with previously treated multiple myeloma2 and minimal residual disease (MRD) negativity in hematologic cancers
    Landgren, C. Ola
    ONCOLOGY-NEW YORK, 2021, 35 (07): : 380 - 380
  • [24] Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series
    Attar, Narsis
    Cirstea, Diana
    Branagan, Andrew R.
    Yee, Andrew J.
    Frigault, Matthew J.
    Raje, Noopur
    BLOOD, 2023, 142
  • [25] Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
    Usmani, Saad Zafar
    Martin, Thomas G.
    Berdeja, Jesus G.
    Jakubowiak, Andrzej J.
    Agha, Mounzer E.
    Cohen, Adam D.
    Deol, Abhinav
    Htut, Myo
    Lesokhin, Alexander M.
    Munshi, Nikhil C.
    O'Donnell, Elizabeth
    Jackson, Carolyn Chang
    Yeh, Tzu-Min
    Banerjee, Arnob
    Zudaire, Enrique
    Madduri, Deepu
    Zhou, Changwei
    Bubuteishvili-Pacaud, Lida
    Lin, Yi
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
    Costa, Luciano J.
    Lin, Yi
    Cornell, R. Frank
    Martin, Thomas
    Chhabra, Saurabh
    Usmani, Saad Z.
    Jagannath, Sundar
    Callander, Natalie S.
    Berdeja, Jesus G.
    Kang, Yubin
    Vij, Ravi
    Godby, Kelly N.
    Malek, Ehsan
    Neppalli, Amarendra
    Liedtke, Michaela
    Fiala, Mark
    Tian, Hong
    Valluri, Satish
    Marino, Jennifer
    Jackson, Carolyn C.
    Banerjee, Arnob
    Kansagra, Ankit
    Schecter, Jordan M.
    Kumar, Shaji
    Hari, Parameswaran
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05): : 326 - 335
  • [27] The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
    Hillengass, Jens
    Cohen, Adam D.
    Agha, Mounzer E.
    Delforge, Michel
    Kerre, Tessa
    Roeloffzen, Wilfried
    Einsele, Hermann
    Goldschmidt, Hartmut
    Weisel, Katja
    Raab, Marc S.
    Scheid, Christof
    Anguille, Sebastien
    Sonneveld, Pieter
    Zweegman, Sonja
    Schecter, Jordan M.
    de Braganca, Kevin C.
    Jackson, Carolyn Chang
    Vlummens, Philip
    Varsos, Helen
    Corsale, Christina
    Madduri, Deepu
    Yeh, Tzu-Min
    Mistry, Pankaj
    Roccia, Tito
    Song, Qingxuan
    Akram, Muhammad
    Costa Filho, Octavio
    Geng, Dong
    Cohen, Yael C.
    van de Donk, Niels W. C. J.
    BLOOD, 2023, 142
  • [28] Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis
    Richardson, Tim
    Schuette, Daniel
    Kobbe, Guido
    Baermann, Ben-Niklas
    Holderried, Tobias A. W.
    Schmitz, Friederike
    Crysandt, Martina
    Hallek, Michael
    Scheid, Christoph
    Holtick, Udo
    Cornely, Oliver A.
    Stemler, Jannik
    Mellinghoff, Sibylle C.
    BLOOD ADVANCES, 2025, 9 (06) : 1370 - 1375
  • [29] CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Usmani, Saad Z.
    Martin, Thomas
    Berdeja, Jesus G.
    Jakubowiak, Andrzej
    Agha, Mounzer
    Cohen, Adam D.
    Deol, Abhinav
    Htut, Myo
    Lesokhin, Alexander
    Munshi, Nikhil C.
    O'Donnell, Elizabeth
    Jackson, Carolyn C.
    Yeh, Tzu-min
    Banerjee, Arnob
    Zudaire, Enrique
    Madduri, Deepu
    Zhou, Changwei
    Pacaud, Lida
    Lin, Yi
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S410 - S411
  • [30] Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.
    Usmani, Saad Zafar
    Berdeja, Jesus G.
    Madduri, Deepu
    Jakubowiak, Andrzej J.
    Agha, Mounzer E.
    Cohen, Adam D.
    Hari, Parameswaran
    Yeh, Tzu-Min
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn Chang
    Allred, Alicia Jones
    Zudaire, Enrique
    Deraedt, William
    Wu, Xiaoling
    Carrasco-Alfonso, Marlene
    Akram, Muhammad
    Lin, Yi
    Martin, Thomas G.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345